Roberts P S, Hughes H N, Fleming P B
Thromb Haemost. 1976 Feb 29;35(1):202-10.
Shorter clotting times were found in the presence of 50 mM Hepes (N-2-hydroxyethylpiperazine-N1-2-ethanesulfonic acid) buffer than of 50mM Imidazole buffer in one-stage assays of factors V and VIII, in modified APTT and PT tests and in tests of the clotting of human plasma by purified human thrombin. All tests were performed at ionic strength 0.155 in the presence of either Hepes. NaOH or Imidazole. HCl buffer, pH 7.4 at 37 degrees. The faster clotting in the presence of Hepes buffer, therefore, is probably due, at least in part, to acceleration by Hepes of thrombin's enzymatic action on fibrinogen and/or of the polymerization of the fibrin monomers. Hepes may also have effects of other blood clotting reactions. Rates of hydrolysis of TAME or BAME (p-toluenesulfonyl- or benzoyl-L-arginine methyl ester) at pH 7.4 37 degrees by purified human bovine thrombin were essentially the same in 200 mM Hepes as in 250 mM Tris. HCl buffer (rates in Hepes. NaOH or Hepes. KOH buffers were compared with those in Tris. HCl plus NaCl for KCl). However, with purified bovine thrombokinase, rates of TAME hydrolysis in Hepes buffer were accelerated and rates of BAME hydrolysis slightly inhibited. Hepes, therefore, reacts with thrombokinase but whether this accelerates (or inhibits) the rate of converting prothrombin to thrombin remains to be determined. In addition, Hepes has an inhibitory effect on clotting since increasing the concentration of Hepes from 50 mM to 200 mM inhibits clotting in the PT, APTT and bovine thrombin-human plasma tests. Hepes buffer is being added to some plasmas and to some reagents used in clotting tests. It is, therefore, important to realize that its concentration must be monitored closely or erroneous results may be obtained in clotting tests and assays of clotting factors. The clotting times were the same in the presence of 50 mM Tris. HCl as in Imidazole. HCl buffers in APTT tests at three ionic strengths but they differed slightly in plasma-thrombin tests. Depending upon the ionic strength, 17 mM Barbital Sodium. HCl buffer inhibited APTT tests but accelerated plasma-thrombin tests. All the buffers tested, therefore, have individual effects on the clotting tests.
在因子V和VIII的一期测定、改良的活化部分凝血活酶时间(APTT)和凝血酶原时间(PT)试验以及纯化的人凝血酶对人血浆凝血的试验中,发现在50 mM 4-(2-羟乙基)-1-哌嗪乙磺酸(Hepes)缓冲液存在下的凝血时间比在50 mM咪唑缓冲液存在下的短。所有试验均在离子强度0.155下进行,存在Hepes、氢氧化钠或咪唑、盐酸缓冲液,pH 7.4,温度37℃。因此,在Hepes缓冲液存在下更快的凝血可能至少部分是由于Hepes加速了凝血酶对纤维蛋白原的酶促作用和/或纤维蛋白单体的聚合。Hepes也可能对其他血液凝固反应有影响。在pH 7.4、37℃下,纯化的人或牛凝血酶对甲苯磺酰-L-精氨酸甲酯(TAME)或苯甲酰-L-精氨酸甲酯(BAME)的水解速率在200 mM Hepes中与在250 mM Tris·HCl缓冲液中基本相同(将Hepes、氢氧化钠或Hepes、氢氧化钾缓冲液中的速率与Tris·HCl加氯化钠或氯化钾中的速率进行比较)。然而,对于纯化的牛凝血激酶,Hepes缓冲液中TAME的水解速率加快,BAME的水解速率略有抑制。因此,Hepes与凝血激酶发生反应,但这是否加速(或抑制)凝血酶原转化为凝血酶的速率仍有待确定。此外,Hepes对凝血有抑制作用,因为将Hepes的浓度从50 mM增加到200 mM会抑制PT、APTT和牛凝血酶-人血浆试验中的凝血。Hepes缓冲液正被添加到一些血浆和一些凝血试验中使用的试剂中。因此,必须认识到必须密切监测其浓度,否则在凝血试验和凝血因子测定中可能会得到错误的结果。在三种离子强度的APTT试验中,50 mM Tris·HCl存在下的凝血时间与咪唑·盐酸缓冲液存在下的相同,但在血浆-凝血酶试验中略有不同。根据离子强度,17 mM巴比妥钠·盐酸缓冲液会抑制APTT试验,但会加速血浆-凝血酶试验。因此,所有测试的缓冲液对凝血试验都有各自的影响。